The estimated Net Worth of Paolo Tombesi is at least $2.37 Миллион dollars as of 27 July 2022. Mr. Tombesi owns over 1,183 units of Epizyme Inc stock worth over $42,189 and over the last 7 years he sold EPZM stock worth over $148,243. In addition, he makes $2,178,460 as Chief Financial Officer at Epizyme Inc.
Paolo has made over 5 trades of the Epizyme Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,183 units of EPZM stock worth $88,654 on 27 July 2022.
The largest trade he's ever made was exercising 7,055 units of Epizyme Inc stock on 19 August 2020 worth over $10,371. On average, Paolo trades about 820 units every 57 days since 2017. As of 27 July 2022 he still owns at least 28,700 units of Epizyme Inc stock.
You can see the complete history of Mr. Tombesi stock trades at the bottom of the page.
Paolo Tombesi serves as Chief Financial Officer of the Company. Prior to joining us, from June 2017 to June 2019 Mr. Tombesi served as the Chief Financial Officer for Insmed Incorporated, or Insmed, a global biopharmaceutical company. Prior to joining Insmed, Mr. Tombesi was Chief Financial and Administrative Officer of Novartis Pharmaceuticals Corporation, a U.S. subsidiary of multinational pharmaceutical company Novartis AG, or Novartis, a position he held from December 2014 through May 2017. Mr. Tombesi was Managing Director and Chief Financial Officer of Novartis Pharma K.K., a Japanese subsidiary of Novartis, from April 2009 to November 2014 and held various finance roles at Novartis from September 2006 to March 2009. Mr. Tombesi held several finance director positions at Bristol-Myers Squibb, a multinational biopharmaceutical company, from August 1996 to September 2006. From January 1988 to July 1996, Mr. Tombesi held various positions in consumer goods at Unilever NV and Johnson & Johnson. Mr. Tombesi holds a B.Ed. in Business and Managerial Economics from Sapienza Università di Roma and a B.A. in Accounting from Duca degli Abruzzi Roma.
As the Chief Financial Officer of Epizyme Inc, the total compensation of Paolo Tombesi at Epizyme Inc is $2,178,460. There are 2 executives at Epizyme Inc getting paid more, with Robert Bazemore having the highest compensation of $4,173,620.
Paolo Tombesi is 56, he's been the Chief Financial Officer of Epizyme Inc since 2019. There are 7 older and 12 younger executives at Epizyme Inc. The oldest executive at Epizyme Inc is Kenneth Bate, 69, who is the Independent Director.
Over the last 11 years, insiders at Epizyme Inc have traded over $122,255,844 worth of Epizyme Inc stock and bought 45,285,781 units worth $322,885,823 . The most active insiders traders include Forest Baskett, Scott D Sandell и Peter J Barris. On average, Epizyme Inc executives and independent directors trade stock every 17 days with the average trade being worth of $394,367. The most recent stock trade was executed by Grant C. Bogle on 9 August 2022, trading 1,217,500 units of EPZM stock currently worth $1,704,500.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
Epizyme Inc executives and other stock owners filed with the SEC include: